The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
Abstract
BACKGROUND At present, biological disease-modifying anti-rheumatic drugs (DMARDs) are the only treatment recommended for patients with ankylosing spondylitis who have not responded to first-line treatment with non-steroidal anti-inflammatory drugs (NSAIDs). The TORTUGA trial investigated the efficacy and safety of filgotinib, an oral selective Janus kinase 1 (JAK1) inhibitor, for the treatment of patients with active ankylosing spondylitis. METHODS In this completed, randomised, double-blind, placebo-controlled, phase 2 trial, we enrolled adult patients from 30 sites in seven countries (Belgium, Bulgaria, Czech Republic, Estonia, Poland, Spain, and Ukraine). Eligible patients had active ankylosing spondylitis and an inadequate response or intolerance to two or more NSAIDs. Patients were randomly assigned (1:1) with an interactive web-based response system to receive filgotinib 200 mg or placebo orally once daily for 12 weeks. Randomisation was stratified by current use of conventional synthetic DMARDs and previous receipt of anti-tumour necrosis factor therapy. The patients, study team, and study sponsor were masked to treatment assignment. The primary endpoint was the change from baseline in ankylosing spondylitis disease activity score (ASDAS) at week 12, which was assessed in the full analysis set (ie, all randomised patients who received at least one dose of study drug). Safety was assessed according to actual treatment received. This trial is registered with ClinicalTrials.gov, number NCT03117270. FINDINGS Between March 7, 2017, and July 2, 2018, 263 patients were screened and 116 randomly assigned to filgotinib (n=58) or placebo (n=58). 55 (95%) patients in the filgotinib group and 52 (90%) in the placebo group completed the study; three (5%) patients in the filgotinib group and six (10%) in the placebo group discontinued treatment. The mean ASDAS change from baseline to week 12 was -1·47 (SD 1·04) in the filgotinib group and -0·57 (0·82) in the placebo group, with a least squares mean difference between groups of -0·85 (95% CI -1·17 to -0·53; p<0·0001). Treatment-emergent adverse events were reported in 18 patients in each group, the most common being nasopharyngitis (in two patients in the filgotinib group and in four patients in the placebo group). Treatment-emergent adverse events led to permanent treatment discontinuation in two patients (a case of grade 3 pneumonia in the filgotinib group and of high creatine kinase in the placebo group). No deaths were reported during the study. INTERPRETATION Filgotinib is efficacious and safe for the treatment of patients with active ankylosing spondylitis who have not responded to first-line pharmacological therapy with NSAIDs. Further investigation of filgotinib for ankylosing spondylitis is warranted. FUNDING Galapagos and Gilead Sciences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“filgotinib, is efficacious in patients with psoriatic arthritis and ankylosing spondylitis”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as van der Heijde et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis
Linden, S. V. D., Valkenburg, H. A., & Cats, A. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270401 · Cited by 5,697
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
van der Heijde, D., Ramiro, S., Landewé, R., Baraliakos, X., Van den Bosch, F., Sepriano, A., Regel, A., Ciurea, A., Dagfinrud, H., Dougados, M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210770 · Cited by 1,568
Self-citationSieper, J., & Poddubnyy, D. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31591-4 · Cited by 1,333
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
van der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A. C., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21913 · Cited by 872
Self-citationLandewé, R., Braun, J., Deodhar, A. A., Dougados, M., Maksymowych, W. P., Mease, P. J., Reveille, J. D., Rudwaleit, M., van der Heijde, D. M. F. M., Stach, C. M., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204231 · Cited by 470
Self-citationStolwijk, C., van Tubergen, A., Castillo-Ortiz, J. D., & Boonen, A. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203582 · Cited by 446
Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32537-5 · Cited by 439
Self-citationGlobal Prevalence of Spondyloarthritis: A Systematic Review and Meta‐Regression Analysis
Stolwijk, C., van Onna, M., Boonen, A., & van Tubergen, A. (2016) · Arthritis Care & Research · doi:10.1002/acr.22831 · Cited by 431
Baeten, D., Østergaard, M., Wei, J. C.-C., Sieper, J., Järvinen, P., Tam, L.-S., Salvarani, C., Kim, T.-H., Solinger, A., Datsenko, Y., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213328 · Cited by 390
van der Heijde, D., Deodhar, A., Wei, J. C., Drescher, E., Fleishaker, D., Hendrikx, T., Li, D., Menon, S., & Kanik, K. S. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210322 · Cited by 376
Self-citationBaker, K. F., & Isaacs, J. D. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 370
Landewé, R., Dougados, M., Mielants, H., van der Tempel, H., & van der Heijde, D. M. F. M. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091793 · Cited by 276
Self-citationWesthovens, R., Taylor, P. C., Alten, R., Pavlova, D., Enríquez-Sosa, F., Mazur, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210104 · Cited by 236
Self-citationKavanaugh, A., Kremer, J., Ponce, L., Cseuz, R., Reshetko, O. V., Stanislavchuk, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210105 · Cited by 229
Self-citationJak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
Haan, C., Rolvering, C., Raulf, F., Kapp, M., Drückes, P., Thoma, G., Behrmann, I., & Zerwes, H.-G. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.012 · Cited by 200
Mease, P., Coates, L. C., Helliwell, P. S., Stanislavchuk, M., Rychlewska-Hanczewska, A., Dudek, A., Abi-Saab, W., Tasset, C., Meuleners, L., Harrison, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32483-8 · Cited by 196
Self-citationThromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott, I. C., Hider, S., & Scott, D. L. (2018) · Drug Safety · doi:10.1007/s40264-018-0651-5 · Cited by 150
Bengtsson, K., Forsblad‐d’Elia, H., Lie, E., Klingberg, E., Dehlin, M., Exarchou, S., Lindström, U., Askling, J., & Jacobsson, L. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1315-z · Cited by 149
Namour, F., Diderichsen, P. M., Cox, E. H., Vayssière, B., der Aa, A. V., Tasset, C. T., & Klooster, G. A. E. V. '. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0240-z · Cited by 138
Self-citationVerden, A., Dimbil, M., Kyle, R. F., Overstreet, B. M., & Hoffman, K. B. (2017) · Drug Safety · doi:10.1007/s40264-017-0622-2 · Cited by 138
Sieper, J., Braun, J., Kay, J., Badalamenti, S., Radin, A. R., Jiao, L., Fiore, S., Momtahen, T., Yancopoulos, G. D., Stahl, N., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204963 · Cited by 127
Jethwa, H., & Bowness, P. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12670 · Cited by 119
Eriksson, J. K., Jacobsson, L., Bengtsson, K., & Askling, J. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209315 · Cited by 113
The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis
Tsui, F. W. L., Tsui, H. W., Akram, A., Haroon, N., & Inman, R. D. (2014) · The Application of Clinical Genetics · doi:10.2147/tacg.s37325 · Cited by 102
The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
Veale, D. J., McGonagle, D., McInnes, I. B., Krueger, J. G., Ritchlin, C. T., Elewaut, D. S., Kanik, K. S., Hendrikx, T. K., Berstein, G., Hodge, J. A., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/key070 · Cited by 93
Self-citationRecent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside
Tanaka, Y. (2015) · The Journal of Biochemistry · doi:10.1093/jb/mvv069 · Cited by 78
The impact of ankylosing spondylitis/axial spondyloarthritis on work productivity
Martindale, J. H., Shukla, R. R., & GOODACRE, J. A. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2015.04.002 · Cited by 74
Genovese, M. C., Westhovens, R., Meuleners, L., der Aa, A. V., Harrison, P., Tasset, C. T., & Kavanaugh, A. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1541-z · Cited by 56
Self-citationWanders, A. J. B., Gorman, J. D., Davis, J. C., Landewé, R., & van der Heijde, D. M. F. M. (2004) · Arthritis Care & Research · doi:10.1002/art.20075 · Cited by 49
Self-citationvan der Heijde, D. M. F. M., Gensler, L. S., Deodhar, A. A., Baraliakos, X., Poddubnyy, D., Farmer, M. K., Baeten, D., Kumke, T., Oortgiesen, M., & Dougados, M. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-eular.7889 · Cited by 16
Self-citationBraun, J., Sieper, J., Aelion, J. A., Emery, P. E., Deodhar, A. A., Porter, B. O., Andersson, M., & Richards, H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-eular.3031 · Cited by 4
Self-citation
Research works printed but not linked: 1
- Maxwell, 2015, TNF-alpha inhibitors for ankylosing spondylitis (review), Cochrane Database Syst Rev, 4
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Coates, L. C., Soriano, E. R., Corp, N., Bertheussen, H., Callis Duffin, K., Campanholo, C. B., Chau, J., Eder, L., Fernández-Ávila, D. G., FitzGerald, O., et al. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00798-0 · Cited by 627
Ankylosing spondylitis: etiology, pathogenesis, and treatments
Zhu, W., He, X., Cheng, K., Zhang, L., Chen, D., Wang, X., Qiu, G., Cao, X., & Weng, X. (2019) · Bone Research · doi:10.1038/s41413-019-0057-8 · Cited by 502
Feagan, B. G., Danese, S., Loftus, E. V., Vermeire, S., Schreiber, S., Ritter, T., Fogel, R., Mehta, R., Nijhawan, S., Kempiński, R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00666-8 · Cited by 462
Self-citation
Metadata
- Authors
- van der Heijde, D., Baraliakos, X., Gensler, L. S., Maksymowych, W. P., Tseluyko, V., Nadashkevich, O., Abi-Saab, W., Tasset, C., Meuleners, L., Besuyen, R., Hendrikx, T., Mozaffarian, N., Liu, K., Greer, J. M., Deodhar, A., & Landewé, R.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 392
- Issue
- 10162
- Pages
- 2378-2387
- ISSN
- 0140-6736
- Cited by
- 242
- References
- 32
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.